- Home
- Publications
- Publication Search
- Publication Details
Title
Issues and promises of bevacizumab in prostate cancer treatment
Authors
Keywords
-
Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 18, Issue 6, Pages 707-717
Publisher
Informa UK Limited
Online
2018-05-21
DOI
10.1080/14712598.2018.1479737
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer
- (2016) Ravi A. Madan et al. BJU INTERNATIONAL
- A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy
- (2016) Rana R. McKay et al. JOURNAL OF CLINICAL ONCOLOGY
- Antiangiogenic therapy in oncology: current status and future directions
- (2016) Gordon C Jayson et al. LANCET
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer
- (2015) Rana R. McKay et al. CANCER
- Regulation of vascular endothelial growth factor in prostate cancer
- (2015) S. de Brot et al. ENDOCRINE-RELATED CANCER
- Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance)
- (2014) Jai N. Patel et al. CANCER
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting Fibroblast Growth Factor Pathways in Prostate Cancer
- (2013) P. G. Corn et al. CLINICAL CANCER RESEARCH
- Contraindicated Use of Bevacizumab and Toxicity in Elderly Patients With Cancer
- (2013) Dawn L. Hershman et al. JOURNAL OF CLINICAL ONCOLOGY
- Androgen up-regulates vascular endothelial growth factor expression in prostate cancer cells via an Sp1 binding site
- (2013) Kurtis Eisermann et al. Molecular Cancer
- Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer
- (2013) Ulka N. Vaishampayan et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Long-term Follow-up of a Phase II Trial of Chemotherapy Plus Hormone Therapy for Biochemical Relapse After Definitive Local Therapy for Prostate Cancer
- (2013) Mari Nakabayashi et al. UROLOGY
- Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer
- (2012) Robert W. Ross et al. CANCER
- Targeting angiogenesis for the treatment of prostate cancer
- (2012) Emmanuel S Antonarakis et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401
- (2012) William Kevin Kelly et al. JOURNAL OF CLINICAL ONCOLOGY
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy–A meta-analysis
- (2011) Amna Sher et al. ACTA ONCOLOGICA
- Genetic polymorphisms in androgen receptor-binding sites predict survival in prostate cancer patients receiving androgen-deprivation therapy
- (2011) C.-N. Huang et al. ANNALS OF ONCOLOGY
- Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis
- (2011) J. Cortes et al. ANNALS OF ONCOLOGY
- Phase II Study of Long-Term Androgen Suppression With Bevacizumab and Intensity-Modulated Radiation Therapy (IMRT) in High-Risk Prostate Cancer
- (2011) Jacqueline Vuky et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Molecular States Underlying Androgen Receptor Activation: A Framework for Therapeutics Targeting Androgen Signaling in Prostate Cancer
- (2011) Peter S. Nelson JOURNAL OF CLINICAL ONCOLOGY
- Tumor angiogenesis: molecular pathways and therapeutic targets
- (2011) Sara M Weis et al. NATURE MEDICINE
- Increased Risk of High-Grade Hypertension With Bevacizumab in Cancer Patients: A Meta-Analysis
- (2010) V. Ranpura et al. AMERICAN JOURNAL OF HYPERTENSION
- A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer
- (2010) Joel Picus et al. CANCER
- Combined targeting of the VEGFr/EGFr and the mammalian target of rapamycin (mTOR) signaling pathway delays cell cycle progression and alters adhesion behavior of prostate carcinoma cells
- (2010) Steffen Wedel et al. CANCER LETTERS
- Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2010) Yang-Min Ning et al. JOURNAL OF CLINICAL ONCOLOGY
- A sex-specific role for androgens in angiogenesis
- (2010) Daniel P. Sieveking et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Bevacizumab
- (2010) F. Kazazi-Hyseni et al. ONCOLOGIST
- Clinical Outcomes in Elderly Patients with Metastatic Colorectal Cancer Receiving Bevacizumab and Chemotherapy: Results from the BRiTE Observational Cohort Study
- (2010) Mark F. Kozloff et al. ONCOLOGY
- Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast Cancer
- (2009) Robert Gray et al. JOURNAL OF CLINICAL ONCOLOGY
- Suppression of Prostate Cancer Nodal and Systemic Metastasis by Blockade of the Lymphangiogenic Axis
- (2008) J. B. Burton et al. CANCER RESEARCH
- Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 Study
- (2008) Giuseppe Di Lorenzo et al. EUROPEAN UROLOGY
- Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)
- (2008) Axel Grothey et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation